ES2570766T3 - Derivatives of 1-benzyl-3-hydroxymethylindazole and its use in the treatment of diseases based on the expression of MCP-1 and CX3CR1 - Google Patents
Derivatives of 1-benzyl-3-hydroxymethylindazole and its use in the treatment of diseases based on the expression of MCP-1 and CX3CR1Info
- Publication number
- ES2570766T3 ES2570766T3 ES09718101T ES09718101T ES2570766T3 ES 2570766 T3 ES2570766 T3 ES 2570766T3 ES 09718101 T ES09718101 T ES 09718101T ES 09718101 T ES09718101 T ES 09718101T ES 2570766 T3 ES2570766 T3 ES 2570766T3
- Authority
- ES
- Spain
- Prior art keywords
- carbon atoms
- hydrogen
- alkyl group
- group
- different
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Transplantation (AREA)
- Psychiatry (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
Abstract
Compuesto de fórmula (I)**Fórmula** en el que: A puede ser -X1- o -X1-O-X2-, en el que X1 puede ser un grupo alquilo que presenta de 1 a 5 átomos de carbono, sustituido opcionalmente 10 con uno o más grupos alquilo que presentan de 1 a 5 átomos de carbono o uno o más grupos alcoxi que presentan de 1 a 3 átomos de carbono, y X2 puede ser un grupo alquilo que presenta de 1 a 5 átomos de carbono, sustituido opcionalmente con uno o más grupos alquilo que presentan de 1 a 5 átomos de carbono, Y puede ser hidrógeno, -OH, -N(R11)(R12), -N(R11)O(R12), en el que R11 puede ser hidrógeno, un grupo alquilo que presenta de 1 a 5 átomos de carbono, un grupo alcoxi que presenta de 1 a 3 átomos de carbono, o R11 junto con R12 forma un heterociclo de 4 a 7 miembros, R12 puede ser hidrógeno, un grupo alquilo que presenta de 1 a 5 átomos de carbono, un grupo alcoxi que presenta de 1 a 3 átomos de carbono, COR', COOR', CON(R')(R'') con R' y R'', que pueden ser iguales o diferentes entre sí, representados por hidrógeno y un grupo alquilo que presenta de 1 a 5 átomos de carbono, o R12 junto con R11 forma un heterociclo de 4 a 7 miembros, R1 y R2, que pueden ser iguales o diferentes entre sí, pueden ser hidrógeno, un grupo alquilo que presenta de 1 a 5 átomos de carbono, R3, R4 y R8, que pueden ser iguales o diferentes entre sí, pueden ser hidrógeno, un grupo alquilo que presenta de 1 a 5 átomos de carbono, un grupo alcoxi que presenta de 1 a 3 átomos de carbono, un átomo de halógeno, -OH, -N(R')(R''), -N(R')COR'', -CN, -CONR'R'', -SO2NR'R'', -SO2R', nitro y trifluorometilo; con R' y R'', que pueden ser iguales o diferentes entre sí, representados por hidrógeno y un grupo alquilo que presenta de 1 a 5 átomos de carbono, R5 puede ser hidrógeno, un grupo alquilo que presenta de 1 a 5 átomos de carbono, un grupo alcoxi que presenta de 1 a 3 átomos de carbono, un átomo de halógeno, -OH, -N(R')(R''), -N(R')COR'', nitro y trifluorometilo, o R5, junto con uno de entre R6 y R7, forma un anillo que presenta 5 o 6 átomos de carbono; con R' y R'', que pueden ser iguales o diferentes entre sí, representados por hidrógeno y un grupo alquilo que presenta de 1 a 5 átomos de carbono, R6 y R7, que pueden ser iguales o diferentes entre sí, pueden ser hidrógeno, un grupo alquilo que presenta de 1 a 5 átomos de carbono, o forman conjuntamente un grupo C>=O, o uno de entre R6 y R7, junto con R5, forma un anillo que presenta 5 o 6 átomos de carbono.Compound of formula (I) ** Formula ** in which: A can be -X1- or -X1-O-X2-, in which X1 can be an alkyl group having 1 to 5 carbon atoms, substituted optionally 10 with one or more alkyl groups having 1 to 5 carbon atoms or one or more alkoxy groups having 1 to 3 carbon atoms, and X2 may be an alkyl group having 1 to 5 carbon atoms, optionally substituted with one or more alkyl groups having 1 to 5 carbon atoms, Y may be hydrogen, -OH, -N (R11) (R12), -N (R11) O (R12), in which R11 can be hydrogen, an alkyl group having 1 to 5 carbon atoms, an alkoxy group having 1 to 3 carbon atoms, or R11 together with R12 forms a 4- to 7-membered heterocycle, R12 can be hydrogen, a group alkyl having 1 to 5 carbon atoms, an alkoxy group having 1 to 3 carbon atoms, COR ', COOR', CON (R ') (R' ') with R' and R '', which can be the same or different from each other í, represented by hydrogen and an alkyl group having 1 to 5 carbon atoms, or R12 together with R11 forms a 4- to 7-membered heterocycle, R1 and R2, which may be the same or different from each other, may be hydrogen, an alkyl group having 1 to 5 carbon atoms, R3, R4 and R8, which may be the same or different from each other, may be hydrogen, an alkyl group having 1 to 5 carbon atoms, an alkoxy group having from 1 to 3 carbon atoms, a halogen atom, -OH, -N (R ') (R' '), -N (R') COR '', -CN, -CONR'R '', -SO2NR 'R', -SO2R ', nitro and trifluoromethyl; with R 'and R' ', which may be the same or different from each other, represented by hydrogen and an alkyl group having 1 to 5 carbon atoms, R5 may be hydrogen, an alkyl group having 1 to 5 atoms of carbon, an alkoxy group having 1 to 3 carbon atoms, a halogen atom, -OH, -N (R ') (R' '), -N (R') COR '', nitro and trifluoromethyl, or R5, together with one of R6 and R7, forms a ring having 5 or 6 carbon atoms; with R 'and R' ', which may be the same or different from each other, represented by hydrogen and an alkyl group having 1 to 5 carbon atoms, R6 and R7, which may be the same or different from each other, may be hydrogen , an alkyl group having 1 to 5 carbon atoms, or together forming a group C> = O, or one of R6 and R7, together with R5, forms a ring having 5 or 6 carbon atoms.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08425141 | 2008-03-07 | ||
| PCT/EP2009/052660 WO2009109654A2 (en) | 2008-03-07 | 2009-03-06 | Novel 1-benzyl-3-hydroxymethyilindazole derivatives and use thereof in the treatment of diseases based on the expression mcp-1 and cx3cr1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2570766T3 true ES2570766T3 (en) | 2016-05-20 |
Family
ID=39672135
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES09718101T Active ES2570766T3 (en) | 2008-03-07 | 2009-03-06 | Derivatives of 1-benzyl-3-hydroxymethylindazole and its use in the treatment of diseases based on the expression of MCP-1 and CX3CR1 |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US8314099B2 (en) |
| EP (1) | EP2262777B8 (en) |
| JP (1) | JP5509102B2 (en) |
| KR (1) | KR101581829B1 (en) |
| CN (1) | CN101959866B (en) |
| AR (1) | AR070813A1 (en) |
| AU (1) | AU2009221063B2 (en) |
| BR (1) | BRPI0908883A2 (en) |
| CA (1) | CA2715065C (en) |
| CY (1) | CY1117504T1 (en) |
| DK (1) | DK2262777T3 (en) |
| EA (1) | EA018185B1 (en) |
| ES (1) | ES2570766T3 (en) |
| GE (1) | GEP20135913B (en) |
| HK (1) | HK1148271A1 (en) |
| HR (1) | HRP20160457T1 (en) |
| HU (1) | HUE026910T2 (en) |
| IL (1) | IL207278A (en) |
| MX (1) | MX2010009624A (en) |
| PL (1) | PL2262777T3 (en) |
| SI (1) | SI2262777T1 (en) |
| UA (1) | UA101350C2 (en) |
| WO (1) | WO2009109654A2 (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2714436C (en) * | 2008-03-07 | 2017-06-27 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | Novel 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40 |
| AU2009221089B2 (en) * | 2008-03-07 | 2013-12-05 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | Novel 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of MCP-1, CX3CR1 and p40 |
| UA108742C2 (en) | 2009-09-23 | 2015-06-10 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF MCP-1 MEDIATED DISEASES | |
| TWI543975B (en) * | 2011-09-13 | 2016-08-01 | Eisai R&D Man Co Ltd | Pyrrolidin-3-yl acetic acid derivatives |
| US8476301B2 (en) | 2011-09-13 | 2013-07-02 | Eisai R&D Management Co., Ltd. | Pyrrolidin-3-ylacetic acid derivative |
| US9013997B2 (en) | 2012-06-01 | 2015-04-21 | Broadcom Corporation | System for performing distributed data cut-through |
| MX2014014657A (en) * | 2012-06-01 | 2015-08-10 | Nogra Pharma Ltd | Bicyclic heterocycles capable of modulating t-cell responses, and methods of using same. |
| WO2014142056A1 (en) | 2013-03-12 | 2014-09-18 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Salt of pyrrolidin-3-yl acetic acid derivative and crystals thereof |
| WO2014142086A1 (en) * | 2013-03-13 | 2014-09-18 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Pyrrolidin-3-yl acetate derivative and piperidin-3-yl acetate derivative |
| CA2989270A1 (en) * | 2015-06-16 | 2016-12-22 | Translatum Medicus, Inc. | Compositions and methods for treating and diagnosing ocular disorders |
| WO2020261158A1 (en) * | 2019-06-25 | 2020-12-30 | Translatum Medicus Inc. | Processes of making 2-((1-benzyl-1h-indazol-3-yl)methoxy)-2-methylpropanoic acid and its derivatives |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1230441B (en) | 1989-02-07 | 1991-10-23 | Acraf | ETHERS OF THE INDAZOLE SERIES |
| IT1253703B (en) | 1991-04-22 | 1995-08-23 | Angelini Francesco Ist Ricerca | USE OF ALCANOIC ACID METHODS OF INDAZOLE TO PREPARE AN ACTIVE DRUG IN THE TREATMENT OF AUTOIMMUNITARY DISEASES |
| IT1293795B1 (en) | 1997-07-28 | 1999-03-10 | Angelini Ricerche Spa | DRUG ACTIVE IN REDUCING THE PRODUCTION OF MCP-1 PROTEIN |
| AU2004278276B2 (en) | 2003-10-07 | 2007-10-18 | Astrazeneca Ab | New 2-substituted, 4-amino-thiazolo(4,5-d) pyrimidines, useful as chemokine receptor antagonists, esp. CX3CR1 |
| US20070043057A1 (en) * | 2005-02-09 | 2007-02-22 | Threshold Pharmaceuticals, Inc. | Lonidamine analogs |
| US7514463B2 (en) * | 2004-08-20 | 2009-04-07 | University Of Kansas | Lonidamine analogues and their use in male contraception and cancer treatment |
| AR053347A1 (en) | 2005-04-06 | 2007-05-02 | Astrazeneca Ab | DERIVATIVES OF [1,3] TIAZOLO [4,5-D] PYRIMIDIN-2 (3H) -ONA 5,7-SUBSTITUTED |
| UA90707C2 (en) | 2005-04-06 | 2010-05-25 | Астразенека Аб | Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives |
| CA2714436C (en) | 2008-03-07 | 2017-06-27 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | Novel 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40 |
| AU2009221089B2 (en) | 2008-03-07 | 2013-12-05 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | Novel 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of MCP-1, CX3CR1 and p40 |
| UA108742C2 (en) | 2009-09-23 | 2015-06-10 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF MCP-1 MEDIATED DISEASES |
-
2009
- 2009-03-06 GE GEAP200911966A patent/GEP20135913B/en unknown
- 2009-03-06 JP JP2010549159A patent/JP5509102B2/en not_active Expired - Fee Related
- 2009-03-06 BR BRPI0908883A patent/BRPI0908883A2/en not_active IP Right Cessation
- 2009-03-06 MX MX2010009624A patent/MX2010009624A/en active IP Right Grant
- 2009-03-06 CN CN2009801074866A patent/CN101959866B/en not_active Expired - Fee Related
- 2009-03-06 PL PL09718101T patent/PL2262777T3/en unknown
- 2009-03-06 ES ES09718101T patent/ES2570766T3/en active Active
- 2009-03-06 AR ARP090100803A patent/AR070813A1/en not_active Application Discontinuation
- 2009-03-06 EA EA201071043A patent/EA018185B1/en not_active IP Right Cessation
- 2009-03-06 WO PCT/EP2009/052660 patent/WO2009109654A2/en active Application Filing
- 2009-03-06 CA CA2715065A patent/CA2715065C/en not_active Expired - Fee Related
- 2009-03-06 DK DK09718101.0T patent/DK2262777T3/en active
- 2009-03-06 SI SI200931403A patent/SI2262777T1/en unknown
- 2009-03-06 AU AU2009221063A patent/AU2009221063B2/en not_active Ceased
- 2009-03-06 HU HUE09718101A patent/HUE026910T2/en unknown
- 2009-03-06 US US12/866,814 patent/US8314099B2/en not_active Expired - Fee Related
- 2009-03-06 KR KR1020107019966A patent/KR101581829B1/en not_active IP Right Cessation
- 2009-03-06 EP EP09718101.0A patent/EP2262777B8/en active Active
- 2009-06-03 UA UAA201009900A patent/UA101350C2/en unknown
-
2010
- 2010-07-29 IL IL207278A patent/IL207278A/en not_active IP Right Cessation
-
2011
- 2011-03-07 HK HK11102288.4A patent/HK1148271A1/en not_active IP Right Cessation
-
2012
- 2012-09-14 US US13/618,948 patent/US8569297B2/en not_active Expired - Fee Related
-
2016
- 2016-04-28 HR HRP20160457TT patent/HRP20160457T1/en unknown
- 2016-05-13 CY CY20161100407T patent/CY1117504T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2570766T3 (en) | Derivatives of 1-benzyl-3-hydroxymethylindazole and its use in the treatment of diseases based on the expression of MCP-1 and CX3CR1 | |
| AR070811A1 (en) | DERIVATIVES OF 1- BENCIL-3- HYDROXIMETHYLENZOL AND ITS USE IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1 AND P40 | |
| BR112014006660A2 (en) | new bicyclic dihydroquinoline-2-one derivatives | |
| AR076754A1 (en) | DIHYDROPIRIMIDINES AND PROCESS OF OBTAINING THE SAME | |
| NZ629025A (en) | Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists | |
| ES2570756T3 (en) | Substituted pyrimidinylpyrrolopyridinone derivatives, process for their preparation and use as kinase inhibitors | |
| CO6210729A2 (en) | DERIVATIVES OF SULFONIL-FENIL-2H- [1,2,4] OXADIAZOL-5-ONA PROCEDURES FOR PREPARATION AND USE AS A PHARMACEUTICAL AGENT | |
| UY31940A (en) | SUBSTITUTED DERIVATIVES OF 4,5- (SUBSTITUTED-PIRIDIN-3-IL) -1-METHYL-1H-INDOL, ITS PHARMACEUTICALLY ACCEPTABLE SALTS, POLYMORPHOS, ROTÁMEROS, PRO-DRUGS, ANANTIOMERS, HYDRATES, SOLVATOS OF THE SAME AND COMPOSITIONS | |
| PE20130375A1 (en) | TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINE COMPOUNDS, C-MET INHIBITORS AND COMPOSITIONS THEREOF | |
| PE20140863A1 (en) | BENZENE COMPOUNDS REPLACED WITH ARYL OR HETEROARYL | |
| AR082112A1 (en) | DERIVATIVES OF IMIDAZOPIRIDINE, ITS PREPARATION PROCEDURE AND ITS APPLICATION IN THERAPEUTICS | |
| PE20210667A1 (en) | BENZAMIDE DERIVATIVES FOR INHIBITION OF ABL1, ABL2 AND BCR-ABL1 ACTIVITY | |
| CO6290657A2 (en) | POLISUSTITUTED DERIVATIVES OF 2-ARIL-6-PHENYL-IMIDAZO [1,2-ALPHA] PIRIDINES ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS | |
| BRPI0809656B8 (en) | atropisomer, compound, prophylactic or therapeutic agent, and pharmaceutical composition | |
| EA201270646A1 (en) | GLUKOSILTSERAMIDSINTAZY INHIBITORS | |
| BRPI0718966B8 (en) | compound, pharmaceutical composition, plk1 inhibitor and antitumor agent | |
| CO2019011604A2 (en) | Vmat2 inhibitor compounds, compositions and methods relating thereto | |
| CO6210701A2 (en) | DERIVATIVES OF ACID AMIDAS 6,7-DIHIDRO-5H-IMIDAZO [1,2-A] IMIDAZOL-3-CARBOXILICO | |
| AR068538A1 (en) | 5-MEMBER HETEROCICLIC COMPOUND WITH SUPPRESSING ACTIVITY OF THE ACID SECRETION | |
| AR078278A1 (en) | ANTAGONISTS OF TIAZOL AND OXAZOL HEPCIDINE, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USE OF THE SAME FOR THE TREATMENT OF ANEMIAS AND ILLNESSES ASSOCIATED WITH IRON DEFICIENCIES. | |
| AR053340A1 (en) | DERIVATIVES OF TRIFLUORMETILBENZAMIDA AND ITS THERAPEUTIC USES | |
| UY31712A1 (en) | NEW DERIVATIVES OF DIOSMETINE, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| CO2018010787A2 (en) | Griseofulvin compound | |
| CY1119296T1 (en) | DICARBOXYLIC ACID UNION | |
| UY32801A (en) | NEW DIHYDROINDOLONE DERIVATIVES, THEIR PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |